Weight-loss jabs could halve risk of obesity-related cancers, study finds
Weight-loss jabs could almost halve the risk of obesity-related cancers, a landmark study suggests.
Cancer experts said the findings were 'transformational' and could herald a 'whole new era of preventive cancer medicine'.
Obesity is associated with 13 different cancers. While losing weight reduces that risk, scientists have calculated weight-loss injections have a bigger protective effect over and above shedding the kilos.
Researchers in Israel studied 6,000 adults with no prior history of cancer, who either underwent bariatric surgery or took glucagon-like peptide-1 receptor agonists (GLP-1RAs) liraglutide (Saxenda), exenatide (Byetta) or dulaglutide (Trulicity). The drugs work by mimicking the GLP-1 hormone in the body, which lowers blood sugar levels and makes people feel fuller for longer.
Although those who had bariatric surgery lost around double the weight of those on weight-loss medication, the study, presented at the European Congress on Obesity in Malaga, Spain, and published in The Lancet's eClinicalMedicine, found the reduction in cancer risk was broadly the same.
Bariatric surgery reduces the risk of cancer by 30-42%, the researchers said. Therefore, accounting for the relative advantage of surgery in reducing patients' weight, the authors found weight-loss drugs were more effective at preventing obesity-related cancer.
'The protective effects of GLP-1RAs against obesity-related cancers likely arise from multiple mechanisms, including reducing inflammation,' said co-lead author Prof Dror Dicker from Hasharon Hospital, Rabin Medical Center, Petah Tikva, Israel.
Newer drugs could prove even more beneficial, he added. 'New generation, highly potent GLP-1RAs with higher efficacy in weight reduction may convey an even greater advantage in reducing the risk of obesity-related cancers, but future research is needed to make sure these drugs do not increase the risk for non-obesity-related cancers.'
A separate study, presented at the conference and published in New England Journal of Medicine, directly compared weight-loss jabs and found patients taking Mounjaro lost about 50% more weight than those taking Wegovy. Patients on Mounjaro typically saw a 20.2% drop in body weight at the end of the trial compared with 13.7% with Wegovy.
Responding to the findings, Prof Mark Lawler, an internationally renowned cancer research expert from Queen's University Belfast, said while this was an observational study and caution was needed interpreting the results, the results were very exciting.
'We already know bariatric surgery cuts obesity-related cancer risk by about a third; these data suggest target GLP-1s may cut that risk by nearly 50% – an approach that would be transformational in preventing obesity-related cancer.
'Biologically, this makes sense, as targeting GLP-1 dampens down inflammation, one of the hallmarks of cancer.
'While further work is required on how it works, these data raise the intriguing possibility that a GLP-1 jab could prevent multiple cancers in the general population, including common cancers like breast and colorectal, and difficult to treat cancers like pancreatic and ovarian. This work could herald a whole new era of preventive cancer medicine.'
Prof Jason Halford, former president of the European Association for the Study of Obesity and head of psychology at Leeds University, said the drugs should also be tested in patients with newly diagnosed cancers to see if they boosted survival chances.
He added the drugs had 'the potential to be a new dawn. And it's not just prevention, weight management in people recently diagnosed with cancer is also critical in terms of outcomes. That would be the next thing to look at. More and more cancers are being associated with obesity.'
A team of 54 international experts from 12 different countries issued a joint statement at the conference, calling for weight-loss drugs to be trialled as a priority for cancer prevention. As a result, a UK team of scientists, based at the University of Manchester and funded by Cancer Research UK, are planning a large-scale clinical trial involving tens of thousands of patients, which they hope to get under way within 'three to five years'.
Dr Matthew Harris, at the Manchester Cancer Research Centre, said weight-loss jabs 'provide genuinely fantastic weight loss, and may provide an intervention that could be delivered on a population-scale, where we have not been able to achieve this before'.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Sky News
4 hours ago
- Sky News
Dozens more killed near food distribution centre in Gaza, claims Hamas-run health ministry
Why you can trust Sky News At least 36 people were killed and 208 wounded when Israeli forces fired towards crowds near a food distribution centre in Gaza on Tuesday morning, according to the Hamas-run territory's health ministry. Footage supplied to Sky News shows people shouting and screaming as they flee explosions in the distance. Dead and wounded people can be seen being carried away from the scene while thick smoke billows into the air. The incident is the latest in a series of reports of Palestinians being killed by Israeli gunfire near one of the distribution centres operated by a new organisation which is permitted by the IDF to hand out aid in the territory. One man seen in the footage says: "We want to live, we want to eat. We have children and wives. We want to live in our homes. Three years of war, bodies ripped apart, all this, for some flour." Humanitarian aid workers and experts have warned Israel's blockade of Gaza and its military campaign has pushed the besieged enclave to the brink of famine. Around 160 people have been killed in shootings near aid sites run by the new Israel and US-backed organisation, the health ministry has said. The Gaza Humanitarian Foundation, which runs the sites, said there has been no violence in or around the distribution centres themselves. However, it has warned people to stay on designated access routes and paused delivery last week while it held talks with Israel's military on improving safety. Israel's military said in a statement its forces fired warning shots at suspects who were advancing and posed a threat to troops "despite warnings that the area is an active combat zone". It said it was aware of reports several people had been injured but its initial inquiry suggests the number "does not align with the information held" by the Israeli military. "The warning shots were fired hundreds of metres from the aid distribution site, prior to its opening hours and toward the suspects who posed a threat to the troops," it said, adding that the details are under review. The government media office of Hamas said: "In a new crime added to the bloody record of the 'Israeli' occupation, the number of victims of the 'Israeli-American aid distribution centres' since Tuesday morning rose to 36 martyrs and more than 208 injuries, bringing the total number of victims of the 'Israeli-American aid distribution centres' to 163 martyrs and 1,495 injuries, all of whom are starving civilians seeking a living under siege and starvation." Israeli government ministers sanctioned It comes as the UK government sanctioned two Israeli government ministers due to their "repeated incitements of violence against Palestinian civilians", the Foreign Office said. The UK imposed sanctions on Itamar Ben-Gvir and Bezalel Smotrich alongside Australia, Canada, New Zealand and Norway. They are being sanctioned in their personal capacities and are now subject to a freeze on UK assets and director disqualifications, and banned from entering the country. The sanctions were criticised by US secretary of state Marco Rubio who said on X: "These sanctions do not advance US-led efforts to achieve a ceasefire, bring all hostages home, and end the war." 1:28 Earlier in the day Greta Thunberg accused Israel of committing "an illegal act" after the Gaza-bound aid boat she was on was seized by the country's military and she was deported to France.
Daily Mail
7 hours ago
- Daily Mail
Doctor who has performed hundreds of autopsies reveals how people 'unknowingly' die of cancer
In 2025, it is predicted that more than 600,000 people will die of cancer in the United States - but within that is a small number who don't even know they have it. While many of these people are treated after their cancer is detected, a pathologist has revealed that he has come across several who unknowingly passed away from the deadly disease. Dr. Wolfe, who has performed numerous autopsies to determine people's cause of death, recently posted a shocking TikTok sharing three stories from within the last few months. In the video, he explained that whilst it is not common, he has performed several autopsies on people - of all different ages - finding their cause of death is not what medics originally thought. The doctor began by discussing how one man had complained of a chronic cough before he died which he had blamed on his smoking. 'He finally gets so severe, where he can't stop coughing. Now, he's coughing up blood, he gets taken to the ER and they do imaging and he has a complete white out on his lungs,' he explained. 'He then codes and dies,' he continued. 'He comes to the autopsy table and I find he does have a horrible pneumonia - one of the worst pneumonias I've ever seen in my career - but as I went through the lung I realized the reason why there was pneumonia. 'It was because there was a cancerous tumor, a small cell carcinoma of the lung that was encasing the airway,' he explained. 'So what happens is it grows into the airway and closes the airway off and causes a pneumonia behind that, it's called the post obstructive pneumonia secondary to malignancy.' He added that pneumonia is not the cause of death, but the 'end point' of the actual underlying cause, which is cancer. 'Without the cancerous tumor blocking the airway, you wouldn't have had the pneumonia,' Dr. Wolfe explained. The doctor then listed another example with a younger patient, who was a man in his early 20s. '[He had] had several months of abdominal pain, weight loss and fevers, also night sweats, and he refused to go to the doctor to investigate this.' 'Then the pain became so intense that he finally did go to the ER and they thought it was going to be some kind of appendicitis or ruptured organ,' the medical professional continued. Sadly, the young man didn't even make it to the CT scanner before he passed away. 'He wasn't able to be revived,' he somberly recalled. When the man was taken to Dr. Wolfe to perform an autopsy, he found him riddled with cancer. 'I opened him up and found cancer in essentially every organ from his clavicles to his pelvis, also in the abdominal wall and the omentum [tissue that drapes over the intestines],' he recalled. The doctor said it was a non-Hodgkin's lymphoma case, explaining: 'The tumor burden just gets so high it messes up the electrolytes for the patient and then they develop cardiac arrhythmia.' The last patient was a 65-year-old man who had colon cancer symptoms, but passed away before he could have a colonoscopy. 'I [did] the autopsy to determine the cause of death and it turns out he did actually have stage four colon cancer that was metastatic widely throughout his abdomen, and also into his lungs and had basically grown through the wall of the colon,' he shared. As per Healthline, there is no definitive length of time someone can have cancer without knowing it, explaining that some cancers can be present for months or years before they're detected. According to a 1990 report from the National Library of Medicine, 11 percent of patients over a 25-year period died from cancer without it being diagnosed. As per the report, over 20,000 autopsies were carried out over a 25-year period, with 700 cancers (11 percent) were found in patients in whom the diagnosis of cancer had not been considered relevant clinically. Doctors always recommend regularly visiting a doctor for health screenings.
The Independent
8 hours ago
- The Independent
Weight-loss drugs were said to be a game changer. Turns out the benefit might be thinner than thought
Common GLP-1 weight loss drugs - including Wegovy and Ozempic - may not work for everyone in a 'real-world' setting, Cleveland Clinic researchers said Tuesday. The reason is that patients may take lower dosages or discontinue their treatment, negatively impacting the ability to control blood sugar levels in those who are pre-diabetic. The findings may have implications for people considering using the drugs, that are taken by more than eight million Americans every year. They've offered an alternative to traditional and taxing weight loss methods, such as diets and fitness. 'Our study shows that patients treated for obesity with semaglutide or trizepatide lost less weight on average in a regular clinical setting compared to what is observed in randomized clinical trials,' Dr. Hamlet Gasoyan, a researcher with Cleveland Clinic, said in a statement. 'According to our data, this could be explained by higher rates of discontinuation and lower maintenance dosages used in clinical practice, compared to randomized clinical trial settings.' Gasoyan was the lead author of the study published on Tuesday in the Obesity Journal. A request for comment from the drugmakers Novo Nordisk and Eli Lilly was not immediately returned to The Independent. The study focuses on drugs with the active ingredients semaglutide and tirzepatide; they include the U.S. Food and Drug-administration approved type 2 diabetes medications Zepbound and Mounjaro. The authors studied their effects on weight loss and blood sugar regulation in a real-world setting. They noted that previous randomized clinical trials have shown the efficacy of those medications. The authors monitored the health of nearly 7,900 adults who were severely obese. Of those, more than 1,300 had pre-diabetes at the study's start and were at a higher risk for developing type 2 diabetes: a chronic condition that affects a person's ability to use insulin and keep blood sugar at normal levels. Participants took the shots between 2021 and 2023. The researchers sorted patients who discontinued their obesity medications into two groups: those who did it within just three months and by three months to a year. The study's follow-up period ended last December. The most common reasoning for discontinuation of treatment in the real-world setting was due to the steep cost of the drugs and insurance, side effects and shortages. Notably, since the study's, prices have started to fall. Of the participants, more than 20 percent discontinued their medications early and 32 percent discontinued their medications late. Furthermore, the authors noted than more than 80 percent had been on the lower dosages needed to sustain a therapeutic effect. For semaglutide, that's equal to or less than 1 milligram and equal to or less than 7.5 milligrams for tirzepatide. Following a year of treatment, the average weight reduction was 3.6 percent among participants who discontinued their treatment early, compared to 6.8 percent for those who discontinued their treatment late. But, those who did not discontinue treatment and were on the highest dosages necessary lost the most weight, at up to 13.7 percent with semaglutide and 18 percent with tirzepatide. Participants had higher odds of achieving 10 percent or greater weight reduction after one year of treatment if they did not discontinue their medications or did so late, were on the highest dosages needed for a therapeutic effect, received tirzepatide, and were women. Tracking the maintenance of blood sugar levels in those with pre-diabetes, the researchers said just a third of those who discontinued their treatment early experienced normal blood sugar levels compared to 41 percent who discontinued their treatment late and 67.9 percent who did not discontinue treatment. Lastly, the researchers observed that while patients who discontinued obesity medications lost significantly less weight compared to those who did not, their weight trajectories remained relatively stable. They said that would be the subject of additional research. 'Our findings about the real-world use patterns of these medications and associated clinical outcomes could inform the decisions of healthcare providers and their patients on the role of treatment discontinuation and maintenance dosage in achieving clinically meaningful weight reductions,' explained Gasoyan.
